Cambient Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Cambient Family Office's VRTX Position: Q2 2026 in Review
Cambient Family Office increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q2 2026, buying an estimated $4.88K and bringing the position to 716 shares worth $356K. The position accounts for 0.04% of the portfolio, ranked #186.
Cambient Family Office first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,751 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Cambient Family Office held 716 shares of Vertex Pharmaceuticals worth $356K as of Q2 2026.
- Cambient Family Office bought 11 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.88K.
- Vertex Pharmaceuticals made up 0.04% of Cambient Family Office's portfolio in Q2 2026, its #186 holding.
- Cambient Family Office first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,751 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Cambient Family Office's 13F filing for Q2 2026, filed 13 Aug 2026.